Uncertainty Looms Over U.S. Vaccine Program Despite Funding Boost

The $5 billion federal program to expedite the development of more potent and durable Covid-19 vaccines is facing bureaucratic hassles and regulatory uncertainty, which could make it harder to curb the spread of the coronavirus and arm the United States against future pandemics. Vaccine makers are confused by murky regulatory guidance, and the program is facing the reality that vaccine development has returned to its slower and more customary pace. While the Biden administration hopes to roll out new vaccine technology by fall 2024, many scientists believe doses are at least several years away.